Cargando…

Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders

Background and study aims: The feasibility and barriars of escitalopram use in patients with functional gastrointestinal disorders (FGIDs) are still debated. We aimed to evaluate the feasibility, safety and efficacy and barriars of escitalopram use in managing FGIDs in the Saudi population. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhowaiter, Saad S., Alshahrani, Amani H., Almarzouqi, Hala F., Alonazi, Gadah K., Alhawassi, Tariq M., AlRasheed, Maha M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240913/
https://www.ncbi.nlm.nih.gov/pubmed/37284319
http://dx.doi.org/10.3389/fphar.2023.1131354
_version_ 1785053877633024000
author Alkhowaiter, Saad S.
Alshahrani, Amani H.
Almarzouqi, Hala F.
Alonazi, Gadah K.
Alhawassi, Tariq M.
AlRasheed, Maha M.
author_facet Alkhowaiter, Saad S.
Alshahrani, Amani H.
Almarzouqi, Hala F.
Alonazi, Gadah K.
Alhawassi, Tariq M.
AlRasheed, Maha M.
author_sort Alkhowaiter, Saad S.
collection PubMed
description Background and study aims: The feasibility and barriars of escitalopram use in patients with functional gastrointestinal disorders (FGIDs) are still debated. We aimed to evaluate the feasibility, safety and efficacy and barriars of escitalopram use in managing FGIDs in the Saudi population. Patients and Methods: We included 51 patients who received escitalopram for irritable bowel syndrome (n = 26), functional heartburn (n = 10), globus sensation (n = 10) or combined disorders (n = 5). We used an irritable bowel syndrome-severity scoring system IBS-SSS), GerdQ questionnaire and Glasgow Edinburg Throat Scale (GETS) to assess disease severity change before and after treatment. Results: The median age was 33 years (25th- 75th percentiles: 29–47), and 26 (50.98%) were males. Forty-one patients experienced side effects (80.39%), but most side effects were mild. The most common side effects were drowsiness/fatigue/dizziness (54.9%), xerostomia (23.53%), nausea/vomiting (21.57%) and weight gain (17.65%). IBS-SSS was 375 (255–430) and 90 (58–205) before and after treatment, respectively (p < 0.001). GerdQ score was 12 (10–13) before treatment and 7 (6–10) after treatment (p = 0.001). GETS score before treatment was 32.5 (21–46) and after treatment became 22 (13–31) (p = 0.002). Thirty-five patients refused to take the medications, and seven patients discontinued the medication. Possible causes of the poor compliance were fear of the medications and not being convinced of taking psychiatric medications for functional disorders (n = 15). Conclusion: Escitalopram could be a safe and effective treatment for functional gastrointestinal disorders. Targeting and managing factors leading to poor compliance could further improve the treatment outcome.
format Online
Article
Text
id pubmed-10240913
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102409132023-06-06 Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders Alkhowaiter, Saad S. Alshahrani, Amani H. Almarzouqi, Hala F. Alonazi, Gadah K. Alhawassi, Tariq M. AlRasheed, Maha M. Front Pharmacol Pharmacology Background and study aims: The feasibility and barriars of escitalopram use in patients with functional gastrointestinal disorders (FGIDs) are still debated. We aimed to evaluate the feasibility, safety and efficacy and barriars of escitalopram use in managing FGIDs in the Saudi population. Patients and Methods: We included 51 patients who received escitalopram for irritable bowel syndrome (n = 26), functional heartburn (n = 10), globus sensation (n = 10) or combined disorders (n = 5). We used an irritable bowel syndrome-severity scoring system IBS-SSS), GerdQ questionnaire and Glasgow Edinburg Throat Scale (GETS) to assess disease severity change before and after treatment. Results: The median age was 33 years (25th- 75th percentiles: 29–47), and 26 (50.98%) were males. Forty-one patients experienced side effects (80.39%), but most side effects were mild. The most common side effects were drowsiness/fatigue/dizziness (54.9%), xerostomia (23.53%), nausea/vomiting (21.57%) and weight gain (17.65%). IBS-SSS was 375 (255–430) and 90 (58–205) before and after treatment, respectively (p < 0.001). GerdQ score was 12 (10–13) before treatment and 7 (6–10) after treatment (p = 0.001). GETS score before treatment was 32.5 (21–46) and after treatment became 22 (13–31) (p = 0.002). Thirty-five patients refused to take the medications, and seven patients discontinued the medication. Possible causes of the poor compliance were fear of the medications and not being convinced of taking psychiatric medications for functional disorders (n = 15). Conclusion: Escitalopram could be a safe and effective treatment for functional gastrointestinal disorders. Targeting and managing factors leading to poor compliance could further improve the treatment outcome. Frontiers Media S.A. 2023-05-22 /pmc/articles/PMC10240913/ /pubmed/37284319 http://dx.doi.org/10.3389/fphar.2023.1131354 Text en Copyright © 2023 Alkhowaiter, Alshahrani, Almarzouqi, Alonazi, Alhawassi and AlRasheed. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Alkhowaiter, Saad S.
Alshahrani, Amani H.
Almarzouqi, Hala F.
Alonazi, Gadah K.
Alhawassi, Tariq M.
AlRasheed, Maha M.
Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
title Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
title_full Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
title_fullStr Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
title_full_unstemmed Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
title_short Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
title_sort feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240913/
https://www.ncbi.nlm.nih.gov/pubmed/37284319
http://dx.doi.org/10.3389/fphar.2023.1131354
work_keys_str_mv AT alkhowaitersaads feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders
AT alshahraniamanih feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders
AT almarzouqihalaf feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders
AT alonazigadahk feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders
AT alhawassitariqm feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders
AT alrasheedmaham feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders